ECSP088778A - FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY - Google Patents

FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Info

Publication number
ECSP088778A
ECSP088778A EC2008008778A ECSP088778A ECSP088778A EC SP088778 A ECSP088778 A EC SP088778A EC 2008008778 A EC2008008778 A EC 2008008778A EC SP088778 A ECSP088778 A EC SP088778A EC SP088778 A ECSP088778 A EC SP088778A
Authority
EC
Ecuador
Prior art keywords
igf
monoclonal antibody
formulation
human monoclonal
preparation
Prior art date
Application number
EC2008008778A
Other languages
Spanish (es)
Inventor
Hanns-Christian Mahler
Adelbert Grossmann
Jan Stracke
Astrid Pappenberger
Oliver Boris Stauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088778A publication Critical patent/ECSP088778A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está relacionada con una formulación de anticuerpo monoclonal humano anti-IGF-1R, un proceso para la preparación y usos del mismo.The present invention is related to an anti-IGF-1R human monoclonal antibody formulation, a process for the preparation and uses thereof.

EC2008008778A 2006-03-28 2008-09-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY ECSP088778A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
ECSP088778A true ECSP088778A (en) 2008-10-31

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008778A ECSP088778A (en) 2006-03-28 2008-09-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Country Status (18)

Country Link
EP (1) EP1998806A1 (en)
JP (1) JP2009531371A (en)
KR (1) KR20080104160A (en)
CN (1) CN101410137A (en)
AR (1) AR060130A1 (en)
AU (1) AU2007229554A1 (en)
BR (1) BRPI0709229A2 (en)
CA (1) CA2647111A1 (en)
CL (1) CL2007000797A1 (en)
CR (1) CR10295A (en)
EC (1) ECSP088778A (en)
IL (1) IL193904A0 (en)
MA (1) MA30345B1 (en)
MX (1) MX2008012295A (en)
NO (1) NO20083895L (en)
RU (1) RU2008142359A (en)
TW (1) TW200815029A (en)
WO (1) WO2007110339A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512356A (en) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー Parenteral Abeta antibody preparation
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
CA2693611A1 (en) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
CA2706403A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
SI2234600T1 (en) * 2007-12-21 2014-12-31 F. Hoffmann-La Roche Ag Antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
JP2013515754A (en) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Novel antibody formulation
JP6294075B2 (en) * 2010-05-28 2018-03-14 ノヴォ ノルディスク アー／エス Stable multi-dose composition comprising antibody and preservative
PT2691112T (en) 2011-03-31 2018-07-10 Merck Sharp & Dohme Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN102363040B (en) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 Antimicrobial peptide preparation for mucosal tissues
ES2871383T3 (en) 2013-04-29 2021-10-28 Hoffmann La Roche Modified Asymmetric Antibodies Binding to the Fc Receptor and Procedures for Use
KR102282134B1 (en) 2013-04-29 2021-07-27 에프. 호프만-라 로슈 아게 Human fcrn-binding modified antibodies and methods of use
CN103505729B (en) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 A kind of stable rabies virus human antibody combination preparation
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A kind of pharmaceutical composition containing adalimumab
CN105916880B (en) 2014-01-15 2020-01-17 豪夫迈·罗氏有限公司 Fc region variants with improved protein A binding
US10206878B2 (en) * 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
AR102198A1 (en) * 2014-10-09 2017-02-08 Regeneron Pharma PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
CN113999312B (en) 2015-06-24 2025-07-04 豪夫迈·罗氏有限公司 Anti-transferrin receptor antibodies with customized affinities
WO2017054646A1 (en) * 2015-09-28 2017-04-06 江苏恒瑞医药股份有限公司 Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
PE20231655A1 (en) 2015-10-02 2023-10-17 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
KR102369014B1 (en) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. Methods for quantifying individual antibodies from mixtures
MX2019004316A (en) 2016-10-25 2019-08-05 Regeneron Pharma Methods and systems for chromatography data analysis.
MX2019013072A (en) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies.
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2020002850A (en) 2017-09-19 2020-07-24 Regeneron Pharma METHODS TO REDUCE THE FORMATION OF PARTICLES AND COMPOSITIONS FORMED FROM THESE.
TWI853823B (en) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
KR20210089215A (en) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody
CN114324882B (en) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 Protein stabilizer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0999853T3 (en) * 1997-06-13 2003-04-22 Genentech Inc Stabilized antibody formulation
DK1399483T3 (en) * 2001-01-05 2010-08-02 Pfizer Antibodies to insulin-like growth factor receptor I
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
US7378503B2 (en) * 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
KR101195295B1 (en) * 2003-04-04 2012-10-29 노파르티스 아게 High concentration antibody and protein formulations
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
RS20060099A (en) * 2003-08-13 2008-08-07 Pfizer Products Inc., Modified human igf-1r antibodies

Also Published As

Publication number Publication date
RU2008142359A (en) 2010-05-10
CR10295A (en) 2008-10-06
KR20080104160A (en) 2008-12-01
IL193904A0 (en) 2011-08-01
WO2007110339A1 (en) 2007-10-04
EP1998806A1 (en) 2008-12-10
NO20083895L (en) 2008-10-24
BRPI0709229A2 (en) 2011-06-28
MA30345B1 (en) 2009-04-01
MX2008012295A (en) 2008-10-09
AU2007229554A1 (en) 2007-10-04
AR060130A1 (en) 2008-05-28
CL2007000797A1 (en) 2008-01-25
CA2647111A1 (en) 2007-10-04
CN101410137A (en) 2009-04-15
JP2009531371A (en) 2009-09-03
TW200815029A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
ECSP088778A (en) FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY
ECSP10010295A (en) FORMULATION OF ANTIBODY
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
CR20110091A (en) NEUTRALIZING ANTIBODIES OF HUMAN CITOMEGALOVIRUS AND USE OF THE SAME
CR20120310A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
CR20120215A (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME
CY1117563T1 (en) HER3 PARTS AND USE OF THESE
EA200900040A1 (en) ANTIBODY MOLECULES THAT ASSOCIATE WITH HUMAN IL-17
CR20150625A (en) COMPOSITION UNDERSTANDING ANTIBODY FIXED TO DOMAIN II OF HER2 AND ITS VARIOUS ACIDS
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
CR20110466A (en) ANTI-ERBB-3 / ANTI-C-MET ANTI-ERBB ANTIBODIES
CO7151488A2 (en) Anti-jagged1 / jagged 2 cross-reaction antibodies, activatable anti-jagged antibodies and methods of use thereof
MX353827B (en) Forms of rifaximin and uses thereof.
BRPI1014544B8 (en) isolated fully human monoclonal anti-il-17f antibody and pharmaceutical composition comprising the same
GT201200318A (en) ANTIBODIES TO GDF8 HUMAN
CR20110204A (en) IMPROVED ANTIBODY MOLECULES
CO6362023A2 (en) ANTI-EGFR / ANTI-IGF-1R BIESPECIFIC ANTIBODIES
ECSP14000329A (en) MOLECULES THAT ARE ANTIBODIES WITH SPECIFICITY FOR HUMAN OX40
CL2012000620A1 (en) Pharmaceutical formulations of an anti cd-20 antibody; use of the formulation to treat disease or disorder that can be corrected by anti-cd20 antibody treatment.
ECSP13012877A (en) SOLID FORMS SDE 3- (5-AMINO-2-methyl -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND USES
JOP20210044A1 (en) Anti-CD38 . antibody
AR057224A1 (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN IL-6
LT2013015A (en) PHARMACEUTICAL COMPOSITIONS
BR112012032008A2 (en) s100a4 antibodies and therapeutic uses thereof
CR10561A (en) VACCINES FOR MALARIA